Century Therapeutics (IPSC) Revenue (2022 - 2025)

Century Therapeutics (IPSC) has 4 years of Revenue data on file, last reported at $109.2 million in Q1 2025.

• On a quarterly basis, Revenue rose 12667.72% year-over-year to $109.2 million in Q1 2025; TTM through Dec 2025 was $109.2 million, a 1556.51% increase from a year earlier, with the FY2025 full-year figure at $109.2 million, up 1556.76% from the prior year.
• Revenue for Q1 2025 stood at $109.2 million, up from $4.2 million in the prior quarter.
• Over the last five years, Revenue for IPSC reached as high as $109.2 million in Q1 2025 and fell as low as $99000.0 in Q2 2023.
• Historically, Revenue has averaged $9.5 million across 4 years, with a median of $855000.0 in 2024.
• Across the five-year window, Revenue slumped 93.35% in 2023 and jumped 12667.72% in 2025, its largest moves.
• Year by year, Revenue stood at $521000.0 in 2022, then plunged by 48.56% to $268000.0 in 2023, then jumped by 1457.09% to $4.2 million in 2024, then surged by 2515.96% to $109.2 million in 2025.
• Per Business Quant data, the three most recent Revenue figures were $109.2 million in Q1 2025, $4.2 million in Q4 2024, and $791000.0 in Q3 2024.